Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme

Table 2

Univariate and multivariate analysis of prognostic factors for progression-free survival in 176 patients with recurrent glioblastoma multiforme.

	Univariate effect			Multivariate effect
	HR	95% CI		HR	95% CI
Gender
Female	1			1
Male	0.87	(0.62–1.43)	0.76	1.24	(0.78–1.67)	0.36
Age (years)	0.95	(0.85–1.12)	0.85	0.98	(0.91–1.25)	0.92
KPS score, (%)
<70	1			1
≥70	0.49	(0.34–0.70)	<0.01	0.53	(0.39–0.73)	0.01
Steroid use
No	1
Yes	0.84	(0.63–1.38)	0.81	0.79	(0.57–1.19)	0.74
Type of first surgery, (%)
Biopsy/partial resection	1			1
Subtotal/total resection	0.86	(0.49–1.42)	0.74	0.95	(0.52–1.54)	0.89
MGMT status
Unmethylated	1			1
Methylated	0.65	(0.44–0.95)	0.03	0.69	(0.52–0.97)	0.04
Time from original diagnosis (months)
<12	1			1
≥12	1.39	(0.76–2.42)	0.33	1.52	(0.85–2.76)	0.21
Second surgery before treatment
No	1
Yes	0.73	(0.42–1.43)	0.51
Maximum tumor diameter (mm)	0.61	(0.37–1.18)	0.19